Kura Oncology (KURA) Non-Current Assets (2014 - 2026)

Kura Oncology (KURA) has 13 years of Non-Current Assets data on file, last reported at $28.8 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 47.04% year-over-year to $28.8 million in Q1 2026; TTM through Mar 2026 was $109.5 million, a 66.24% increase from a year earlier, with the FY2025 full-year figure at $29.7 million, up 93.74% from the prior year.
• Non-Current Assets for Q1 2026 stood at $28.8 million, down from $29.7 million in the prior quarter.
• Over the last five years, Non-Current Assets for KURA reached as high as $29.7 million in Q4 2025 and fell as low as $9.1 million in Q2 2023.
• Historically, Non-Current Assets has averaged $16.8 million across 5 years, with a median of $15.3 million in 2024.
• Across the five-year window, Non-Current Assets slipped 21.89% in 2023 and jumped 93.74% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $9.9 million in 2022, then soared by 66.54% to $16.5 million in 2023, then declined by 6.83% to $15.3 million in 2024, then soared by 93.74% to $29.7 million in 2025, then retreated by 3.13% to $28.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $28.8 million in Q1 2026, $29.7 million in Q4 2025, and $28.7 million in Q3 2025.